Intermittent hormone therapy in nonmetastatic prostate cancer.

No abstract is available for this paper.

• Publication year

  2006

• Venue

  Clinical Genitourinary Cancer

• Publication date

  2006-09-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.3816/CGC.2006.N.030PMID 17026802
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Intermittent androgen suppression for locally advanced and metastatic prostate cancer: preliminary report of a prospective multicenter study.

  2004cited by this paper
• Androgen receptor in prostate cancer.

  2004cited by this paper
• Hormonal treatment alone for locally advanced prostate cancer

  2004cited by this paper
• Neuroendocrine peptides in the prostate

  2004cited by this paper
• Intermittent maximal androgen blockade in patients with metastatic prostate cancer: an EORTC feasibility study.

  2003cited by this paper
• Intermittent androgen suppression in patients with prostate cancer

  2003cited by this paper
• Intermittent Androgen Deprivation for Patients With Recurrent/Metastatic Prostate Cancer

  2003cited by this paper
• Overview consensus statement. Newer approaches to androgen deprivation therapy in prostate cancer.

  2002cited by this paper
• Studies on prostatic cancer: I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. 1941.

  2002cited by this paper
• Androgen blockade in prostate cancer in 2002: major benefits on survival in localized disease.

  2002cited by this paper
• Predictive factors of biochemical progression in prostate cancer patients treated with intermittent androgen suppression

  2002cited by this paper
• Intermittent androgen suppression in prostate cancer: the Canadian experience.

  2002cited by this paper
• Intermittent versus continuous total androgen blockade in the treatment of patients with advanced hormone-naive prostate cancer: results of a prospective randomized multicenter trial.

  2002cited by this paper
• Studies on prostatic cancer. I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. 1941.

  2002cited by this paper
• Hormone-refractory prostate cancer: a multi-step and multi-event process

  2001cited by this paper
• A mechanism for androgen receptor-mediated prostate cancer recurrence after androgen deprivation therapy.

  2001cited by this paper
• Overview consensus statement.

  2001cited by this paper
• Intermittent androgen deprivation in prostate cancer patients: factors predictive of prolonged time off therapy.

  2000cited by this paper
• Hormone therapy for patients with prostate carcinoma

  2000cited by this paper
• Natural history of progression after PSA elevation following radical prostatectomy.

  1999cited by this paper
• The biology of hormone refractory prostate cancer. Why does it develop?

  1999cited by this paper
• Intermittent androgen deprivation for clinically localized prostate cancer: initial experience.

  1998cited by this paper
• Osteoporosis after orchiectomy for prostate cancer.

  1997cited by this paper
• Transdifferentiation of cultured human prostate cancer cells to a neuroendocrine cell phenotype in a hormone-depleted medium.

  1997cited by this paper
• Resistance to apoptosis and up regulation of Bcl-2 in benign prostatic hyperplasia after androgen deprivation.

  1997cited by this paper
• Bone fractures associated with luteinizing hormone‐releasing hormone agonists used in the treatment of prostate carcinoma

  1997cited by this paper
• Synergistic activation of androgen receptor by androgen and luteinizing hormone‐releasing hormone in prostatic carcinoma cells

  1997cited by this paper
• Androgen-independent prostate cancer progression in the TRAMP model.

  1997cited by this paper
• Androgen receptors in prostate cancer.

  1996cited by this paper
• The role of the p53 tumor suppressor gene in prostate cancer: a possible biomarker?

  1996cited by this paper
• Effects of intermittent androgen suppression on the stem cell composition and the expression of the TRPM-2 (clusterin) gene in the Shionogi carcinoma.

  1996cited by this paper
• Intermittent androgen suppression with leuprolide and flutamide for prostate cancer: a pilot study.

  1996cited by this paper
• Clustered p53 immunostaining: a novel pattern associated with prostate cancer progression.

  1996cited by this paper
• Endocrine control of prostate cancer.

  1995cited by this paper
• Androgen suppressed apoptosis is modified in p53 deficient mice.

  1995cited by this paper
• Intermittent androgen suppression in the treatment of prostate cancer: a preliminary report.

  1995cited by this paper
• Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer.

  1995cited by this paper
• Goserelin acetate and flutamide versus bilateral orchiectomy: a phase III EORTC trial (30853). EORTC GU Group and EORTC Data Center.

  1993cited by this paper
• Effects of intermittent androgen suppression on androgen‐dependent tumors. Apoptosis and serum prostate‐specific antigen

  1993cited by this paper
• Clinical implications of the p53 tumor-suppressor gene.

  1993cited by this paper
• BCL2 protein is topographically restricted in tissues characterized by apoptotic cell death.

  1991cited by this paper
• Relation of endocrine‐paracrine cells to cell proliferation in normal, hyperplastic, and neoplastic human prostate

  1991cited by this paper
• Effects of androgen withdrawal on the stem cell composition of the Shionogi carcinoma.

  1990cited by this paper
• A controlled trial of leuprolide with and without flutamide in prostatic carcinoma.

  1989cited by this paper
• Adaptation versus selection as the mechanism responsible for the relapse of prostatic cancer to androgen ablation therapy as studied in the Dunning R-3327-H adenocarcinoma.

  1981cited by this paper
• Hormonal control of growth and progression in tumors of Nb rats and a theory of action.

  1977cited by this paper

• Prostate Cancer: Do We Always have to Treat for Cure?

  2013cites this paper
• Changes in PSA kinetics predict metastasis‐free survival in men with PSA‐recurrent prostate cancer treated with nonhormonal agents

  2012cites this paper
• Long‐term overall survival and metastasis‐free survival for men with prostate‐specific antigen‐recurrent prostate cancer after prostatectomy: analysis of the Center for Prostate Disease Research National Database

  2011cites this paper
• Prostate cancer in elderly men.

  2008cites this paper